Adjunctive antiepileptic drugs in adult epilepsy: How the first add-on could be the last

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 7, 2010, Pages 1053-1067

  Cretin, Benjamin ^a,b   Hirsch, Edouard ^a  

^a CNRS   (France)

^b CTRS   (France)

Author keywords

Adjunctive; Antiepileptic drug; Epilepsies; Treatment

Indexed keywords

ACETAZOLAMIDE; BENZODIAZEPINE; CARBAMAZEPINE; CLOBAZAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; PROGABIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANOREXIA; ASTHENIA; CLINICAL TRIAL; COMORBIDITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPTOGENESIS; FOCAL EPILEPSY; HUMAN; MONOTHERAPY; MOOD DISORDER; NAUSEA; NEPHROLITHIASIS; PARESTHESIA; PHYSICIAN; PRESCRIPTION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOMNOLENCE; STOMACH PAIN; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTICONVULSANTS; DECISION MAKING; DRUG THERAPY, COMBINATION; EPILEPSY; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; QUALITY OF LIFE; SEIZURES; TREATMENT OUTCOME;

EID: 77951264257     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003709755     Document Type: Review

References (91)

1. Forsgren L. Prevalence of epilepsy in adults in northern Sweden. Epilepsia 1992;33(3):450-458
2. Chang BS, Lowenstein DH. Epilepsy. N Engl J Med 2003;349:1257-1266
3. Forsgren L, Beghi E, Oun A, et al. The epidemiology of epilepsy in Europe--a systematic review. Eur J Neurol 2005;12(4):245-253 (Pubitemid 40477131)
4. Cockerell OC, Johnson AL, Sander JW, et al. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346(8968):140-144
5. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-151
6. Schiller Y. Seizure relapse and development of drug resistance following long-term seizure remission. Arch Neurol 2009;66(10):1233-1239
7. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7):1094-1120 (Pubitemid 44086745)
8. Rogawski MA, L€oscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5(7):553-564 (Pubitemid 38868551)
9. Baulac M. New antiepileptic drugs: new therapeutic options. Rev Neurol (Paris) 2002;158(5 Pt 2):4S46-54 (Pubitemid 34534846)
10. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30(4):389-399 (Pubitemid 19194714)
11. Marson AG, Al-Kharusi AM, Alwaidh M, et al.; SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007;369(9566):1000-1015
12. Brodie MJ, Perucca E, Ryvlin P, et al.; Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68(6):402-408 (Pubitemid 46208740)
13. Chadwick D. Valproate in the treatment of partial epilepsies. Epilepsia 1994;35(Suppl 5):S96-8 (Pubitemid 24274714)
14. Crawford P, Chadwick D. A comparative study of progabide, valproate, and placebo as add-on therapy in patients with refractory epilepsy. J Neurol Neurosurg Psychiatry 1986;49(11):1251-1257 (Pubitemid 17174026)
15. Brodie MJ, Mumford JP. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group. Epilepsy Res 1999;34(2-3):199-205
16. Willmore LJ, Shu V, Wallin B. Efficacy and safety of add-on divalproex sodium in the treatment of complex partial seizures. The M88-194 Study Group. Neurology 1996;46(1):49-53 (Pubitemid 26156101)
17. Perucca E, Yasothan U, Clincke G, et al. Lacosamide. Nat Rev Drug Discov 2008;7(12):973-974
18. Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000;41(11):1364-1374
19. Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000;41(12):1597-1607 (Pubitemid 32002734)
20. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partialonset seizures. Epilepsia 2007;48:1308-1317 (Pubitemid 47063096)
21. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures: U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993;43(11):2284-2291
22. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures : a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35(1):113-121 (Pubitemid 24074474)
23. Schapel GJ, Beran RG, Vajda FJ, et al. Double blind, placebo controlled, cross-over study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993;56(5):448-453 (Pubitemid 23171770)
24. French JA, Kanner AM, Bautista J, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62(8):1261-1273
25. Faught E, Morris G, Jacobson M, et al. Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group. Epilepsia 1999;40(8):1135-1140 (Pubitemid 29372630)
26. Buchanan N. Lamotrigine: clinical experience in 200 patients with epilepsy with follow-up to four years. Seizure 1996;5(3):209-214 (Pubitemid 26345844)
27. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997;26(3):423-432
28. Marciani MG, Stanzione P, Mattia D, et al. Lamotrigine add-on therapy in focal epilepsy: electroencephalographic and neuropsychological evaluation. Clin Neuropharmacol 1998;21(1):41-47 (Pubitemid 28078334)
29. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res 2007;73:1-52 (Pubitemid 46091734)
30. Chung S, Sperling MR, Biton V, et al. Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures. Epilepsia 2007;48:321 (Pubitemid 47063096)
31. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al. SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50(3):443-453
32. Anhut H, Ashman P, Feuerstein TJ, et al. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a doubleblind, placebo-controlled study: the International Gabapentin Study Group. Epilepsia 1994;35:795-801
33. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:1114-1117
34. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebocontrolled, parallel-group study. Neurology 1993;43:2292-2298
35. Sivenius J, Kalviainen R, Ylinen A, et al. Double-blind study of Gabapentin in the treatment of partial seizures. Epilepsia 1991;32:539-542
36. French JA, Kugler AR, Robbins JL, et al. Dose--response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60:1631-1637 (Pubitemid 36618090)
37. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose--response study in adults with partial seizures. Epilepsia 2004;45:20-27 (Pubitemid 38063660)
38. Beydoun A, Uthman BM, Kugler AR, et al. Pregabalin 1008-009 Study Group. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005;64:475-480 (Pubitemid 40189866)
39. Elger CE, Brodie MJ, Anhut H, et al. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixeddose treatment in a double-blind, placebo-controlled study. Epilepsia 2005;46:1926-1936 (Pubitemid 44922003)
40. Harden CL, Lazar LM, Pick LH, et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 1999;40(8):1129-1134
41. Gil-Nagel A, Zaccara G, Baldinetti F, et al. Add-on treatment with pregabalin for partial seizures with or without generalisation: pooled data analysis of four randomised placebo-controlled trials. Seizure 2009;18(3):184-192
42. Oles KS, Penry JK, Cole DL, et al. Use of acetazolamide as an adjunct to carbamazepine in refractory partial seizures. Epilepsia 1989;30(1):74-78
43. Ben-Menachem E, Henrisksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-543 (Pubitemid 26169188)
44. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebocontrolled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages: Topiramate YD Study Group. Neurology 1996;46:1684-1690 (Pubitemid 26185793)
45. Privitera M, Fincham R, Penry J, et al. Topiramate placebocontrolled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000 mg daily dosages: Topiramate YE Study Group. Neurology 1996;46:1678-1683 (Pubitemid 26185792)
46. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-224 (Pubitemid 26394543)
47. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993;15:67-73 (Pubitemid 23152402)
48. Faught E, Ayala R, Montouris G, et al. The Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57:1774-1779 (Pubitemid 33096682)
49. Sackellares JC, Ramsay RE, Wilder BJ, et al. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;45:610-617
50. Ziemann AE, Schnizler MK, Albert GW, et al. Seizure termination by acidosis depends on ASIC1a. Nat Neurosci 2008;11(7):816-822
51. Varadkar S, Duncan JS, Cross JH. Acetazolamide and autosomal dominant nocturnal frontal lobe epilepsy. Epilepsia 2003;44(7):986-987 (Pubitemid 36842193)
52. Lombroso CT, Davidson DT Jr, Gross-Bianchi ML. Further evaluation of acetazolamide (Diamox) in treatment of epilepsy. JAMA 1956;160:268-272
53. Rossetti AO, Jallon P. Traitement médical des épilepsies in Traité de Neurologie. Epilepsies, Ed. DOIN Groupe Liaisons; 2007. p. 275-298
54. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000;41(Suppl 1):S66-71 (Pubitemid 30202345)
55. Baulac M, Leppik IE. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 2007;75(2-3):75-83 (Pubitemid 47048652)
56. Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures: European Levetiracetam Study Group. Epilepsia 2000;41:1179-1186
57. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000;41:1276-1283
58. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000;9:80-87 (Pubitemid 30209795)
59. Boon P, Chauvel P, Pohlmann-Eden B, et al. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res 2002;48(1-2):77-89 (Pubitemid 34127719)
60. Wilensky AJ, Ojemann LM, Temkin NR, et al. Clorazepate and phenobarbital as antiepileptic drugs: a double-blind study. Neurology 1981;31(10):1271-1276
61. Brodie MJ, Mumford JP. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group. Epilepsy Res 1999;34(2-3):199-205
62. Schmidt D, Rohde M, Wolf P, et al. Clobazam for refractory focal epilepsy. A controlled trial. Arch Neurol 1986;43(8):824-826 (Pubitemid 16034233)
63. Farhat G, Yamout B, Mikati MA, et al. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002;58(9):1348-1353 (Pubitemid 34507160)
64. Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987;28(Suppl 3):S37-45 (Pubitemid 18021820)
65. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003;2(6):347-356 (Pubitemid 38352562)
66. Grünewald RA, Thompson PJ, Corcoran R, et al. Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psychiatry 1994;57(9):1057-1063
67. Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001;15(3):217-230 (Pubitemid 32281182)
68. Jammoul F, Wang Q, Nabbout R, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol 2009;65(1):98-107
69. O'brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 2005;66(Suppl 2):28-33
70. Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55:1757-1758
71. French JA, Kanner AM, Bautista J, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62(8):1252-1260
72. Benbadis SR. The management of idiopathic generalized epilepsies. Acta Neurol Scand Suppl 2005;181:63-67 (Pubitemid 41687356)
73. Perucca E. The management of refractory idiopathic epilepsies. Epilepsia 2001;42(Suppl 3):31-35 (Pubitemid 32781378)
74. Beran RG, Berkovic SF, Dunagan FM, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 1998;39(12):1329-1333 (Pubitemid 29005633)
75. Gericke A, Picard F, De Saint-Martin A, et al. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-eeg-controlled, open study. Epileptic Disord 1999;1(3):159-165
76. Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Levetiracetam N01057 Study Group. Neurology 2007;69:1751-1760 (Pubitemid 350059304)
77. Noachtar S, Andermann E, Meyvisch P, et al. N166 levetiracetam study group Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008;70:607-616 (Pubitemid 351294638)
78. Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening of seizures. Epilepsia 1998;39:5-17 (Pubitemid 28116836)
79. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic----clonic seizures. Topiramate YTC Study Group. Neurology 1999;52:1330-1337 (Pubitemid 29190520)
80. Biton V, Bourgeois BF, YTC/YTCE Study Investigators. Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol 2005;62(11):1705-1708 (Pubitemid 41626666)
81. Resor SR Jr, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology 1990;40(11):1677-1681 (Pubitemid 20383130)
82. Kothare SV, Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol 2008;4(4):493-506 (Pubitemid 351728521)
83. Beghi E, Gatti G, Tonini C, et al; BASE Study Group. Adjunctive therapy vs. alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003;57(1):1-13 (Pubitemid 38045463)
84. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314-319 (Pubitemid 30075244)
85. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002;58(8 Suppl 5):S2-8 (Pubitemid 34415365)
86. Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998;51(5):1256-1262 (Pubitemid 28520540)
87. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008;70(1):54-66
88. French JA, Faught E. Rational polytherapy. Epilepsia 2009;50(Suppl 8):63-68
89. Devinsky O. Patients with refractory seizures. N Engl J Med 1999;340(20):1565-1570 (Pubitemid 29228187)
90. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2009 [Epub ahead of print]
91. Langfitt JT, Wiebe S. Early surgical treatment for epilepsy. Curr Opin Neurol 2008;21(2):179-183 (Pubitemid 351644160)